Fig. 1
Clinicopathologic characteristics of PDE10A expression in ovarian cancer. A Kaplan-Meyer overall survival analysis of TCGA ovarian cystadenocarcinoma patients stratified by PDE10A mRNA expression levels. PDE10Ahigh and PDE10Alow correspond to mRNA expression 2x higher (n = 16) and 2 × lower (n = 154) than mean PDE10A mRNA levels in the population, respectively; PDE10Amedium, remainder patients (n = 132). B PDE10A protein levels in ovarian cancer cell lines and normal ovarian surface epithelial (OSE) cells measured by western-blotting. GAPDH was used as the loading control. HOSEpic are primary OSE cells, while IOSE-80 and IOSE-7576 are immortalized OSE cell lines. C Comparison of PDE10A expression in normal ovary tissue (from GTEx database; n = 88) and ovarian cancer (from TCGA; n = 426) using GEPIA. D PDE10A mRNA levels measured by qPCR in ovary tumor (n = 59) and normal ovary (n = 14) clinical specimens deposited at our institutional Biobank. Relative expression was calculated with the ΔCt method using GPS1 as housekeeping gene. Error bars, ± SD, **p < 0.01 (Unpaired two-tailed students t-test). E PDE10A mRNA expression in normal human tissue from the GTEx Portal (top 16 tissues included). F–H iPathway Guide impact analysis of genes differentially expressed when comparing TCGA ovarian tumors with PDE10AHIGH vs. PDE10ALOW mRNA levels. In this comparison, 1,510 differentially expressed (DE) genes were identified out of a total of 19,331 genes with measured expression using thresholds of log2-fold change ± 0.6 and adjusted p-value < 0.1. F Each pathway is represented as a single dot, with significant pathways shown in red and yellow, and non-significant in black. G Hub genes and interactions for the Pathways in Cancer pathway. Genes with elevated mRNA expression depicted in red and genes with decreased mRNA expression depicted in blue. H Log2-fold change for the Pathways in Cancer gene set